You just read:

HLS Therapeutics Announces that Amarin's REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint

News provided by

HLS Therapeutics Inc.

Sep 24, 2018, 05:30 ET